Looking at the full year numbers, we see that the revenue jumped by one per cent to reach Rs.7318.63 crore, while its EBITDA fell by 36 per cent to Rs 266.73 crore.

Subros reported strong quarter for Q4FY18 with operational profit and net profit recording strong growth compared to previous year.

The research houses upgraded Sun Pharma’s rating after its Q4FY18 results. It urged more than 7 per cent in Monday’s trade, uplifting the Nifty Pharma Index by 2.4 per cent. The stock bounced back from 435 level up to 61.8 per cent retracement of the downward rally from 539 levels.

Caplin Point Laboratories reported mixed results across the board. The revenue and operating profit grew strongly, while bottom-line increased minimally.

The PAT for the quarter came in at Rs. 7.85 crore, yoy increase of 74.1 per cent. This was partly due to sharp decline in interest expenses by 57.9 per cent yoy.

Mid-cap index is off its provisional low level and has bounced back from its major support at 15,565. After consolidating for three daily sessions at the low levels, Mid-cap index has surged for two consecutive days, hitting near 38.2 per cent retracement of the prior downward rally in May 2018.

The PAT for the quarter came in at Rs. 5.94 crore, yoy increase of 132 per cent. This was due to sharp decline in interest expenses by 46 per cent yoy.

The PAT for the quarter came in at Rs. 7.69 crore, yoy increase of 4.9 per cent.

The stock of Manpasand Beverages extended its losing streak on Monday and has been losing for the last four days and has fallen by 22.67 per cent in the period. The fall was triggered by the resignation of its auditor Deloitte Haskins & Sells.